The study conducted by Odak and colleagues demonstrated that transgenic integrated T cells, which were genetically modified to express CD19-redirected chimeric antigen receptor (CAR) known as GSH6, exhibited favorable therapeutic outcomes in preclinical mouse models while also displaying resistance to tumor re-challenges even after 100 days of administration [231]. This evidence concerns the gene CD19 and neoplasm.